SGMO · Sangamo Therapeutics, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $39.55M | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $112.67M | $111.52M | $234.06M | $249.90M | $230.82M | $180.65M |
| SG&A | $34.89M | $44.73M | $61.17M | $62.68M | $63.22M | $67.10M |
| Total Operating Expenses | $160.79M | $161.77M | $450.24M | $312.58M | $294.04M | $247.74M |
| D&A | $3.96M | $5.11M | $15.06M | $12.11M | $9.44M | $5.68M |
| Operating Income | ($121.24M) | ($103.97M) | ($274.00M) | ($201.28M) | ($183.34M) | ($129.55M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($568.0K) | ($167.0K) | ($5.07M) | $429.0K | $306.0K | $345.0K |
| Net Income | ($122.93M) | ($97.94M) | ($257.83M) | ($192.28M) | ($178.29M) | ($121.00M) |
| EPS - Basic | ($0.44) | ($0.49) | ($1.48) | ($1.25) | ($0.90) | - |
| EPS - Diluted | ($0.44) | ($0.49) | ($1.48) | ($1.25) | ($0.90) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.95M | $41.92M | $45.20M | $100.44M | $178.87M | $131.33M |
| Accounts Receivable | $371.0K | $526.0K | $923.0K | $3.68M | $6.01M | $5.22M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $14.44M | $15.48M | $15.26M | $22.42M | $9.76M | $12.55M |
| Current Assets | $35.83M | $51.69M | $94.33M | $300.33M | $398.77M | $659.67M |
| Total Assets | $59.74M | $101.64M | $165.32M | $562.51M | $721.92M | $938.55M |
| Current Liabilities | $42.47M | $45.80M | $47.73M | $111.71M | $127.89M | $143.55M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $74.01M | $78.86M | $82.43M | $267.55M | $346.58M | $441.18M |
| Stockholders' Equity | ($14.27M) | $22.77M | $82.89M | $294.96M | $375.34M | $498.23M |
| Retained Earnings | ($1.63B) | ($1.50B) | ($1.41B) | ($1.15B) | ($956.27M) | ($777.98M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($97.21M) | ($67.14M) | ($224.84M) | ($223.63M) | ($233.25M) | $169.88M |
| Investing Cash Flow | ($102.0K) | $37.52M | $153.53M | $59.28M | $248.20M | ($271.63M) |
| Financing Cash Flow | $70.75M | $28.38M | $14.59M | $84.66M | $32.86M | $153.10M |
| CapEx | $102.0K | $267.0K | $21.16M | $20.17M | $23.28M | $14.71M |
| Free Cash Flow | ($97.31M) | ($67.41M) | ($246.00M) | ($243.80M) | ($256.53M) | $155.16M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -306.5% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% |
| EBITDA margin | -296.5% | -171.0% | -146.9% | -170.0% | -157.1% | -104.8% |
| Net margin | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% |
| Free cash flow margin | -246.0% | -116.6% | -139.6% | -219.0% | -231.7% | 131.3% |
| FCF / Net income | 0.79 | 0.69 | 0.95 | 1.27 | 1.44 | -1.28 |
| R&D / Revenue | 284.9% | 192.9% | 132.8% | 224.5% | 208.5% | 152.8% |
| SG&A / Revenue | 88.2% | 77.4% | 34.7% | 56.3% | 57.1% | 56.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -205.8% | -96.4% | -156.0% | -34.2% | -24.7% | -12.9% |
| Return on equity | 861.6% | -430.1% | -311.1% | -65.2% | -47.5% | -24.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 |
| Quick ratio | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 |
| Cash ratio | 0.49 | 0.92 | 0.95 | 0.90 | 1.40 | 0.91 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -4.19 | 4.46 | 1.99 | 1.91 | 1.92 | 1.88 |
| Liabilities / Assets | 1.24 | 0.78 | 0.50 | 0.48 | 0.48 | 0.47 |
| Efficiency | ||||||
| Asset turnover | 0.66 | 0.57 | 1.07 | 0.20 | 0.15 | 0.13 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 3d | 3d | 2d | 12d | 20d | 16d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 9.0x | 1.1x | 1.6x | 2.7x | - |
| P / S | 3.0x | 3.6x | 0.5x | 4.4x | 9.1x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -31.6% | -67.2% | 58.3% | 0.5% | -6.3% | 15.4% |
| Revenue CAGR (3y) | -29.2% | -19.5% | 14.2% | 2.8% | 78.7% | 47.9% |
| Revenue CAGR (5y) | -19.7% | -10.8% | 55.5% | 24.9% | 41.7% | 24.5% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -16.6% | 62.1% | -36.1% | -9.8% | -41.5% | -23.2% |
| Net income growth (YoY) | -25.5% | 62.0% | -34.1% | -7.8% | -47.3% | -27.1% |
| EPS growth (YoY) | 10.2% | 66.9% | -18.4% | -38.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -44.4% | 72.6% | -0.9% | 5.0% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -72.5% | -71.9% | -21.4% | -24.7% | 15.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$39.55M totalReportable Segment$39.55M · 100.0%
Product / service
$25.60M totalLicense$18.00M · 70.3%
Initial License$7.60M · 29.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-28.87
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing SANGAMO THERAPEUTICS against the 5 most active filers in the same SIC group.